The disclosure provides orally administrable capsules comprising abuse-resistant, pharmaceutical formulations which comprise abuse-susceptible active agents such as opioids. The formulations provide abuse resistance by having a sufficiently high viscosity that substantially prevents the formulation and opioid therein, from being drawn into a syringe, at room temperature or higher, either alone or when mixed with water or other liquids.